Segall Bryant & Hamill LLC Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT

Segall Bryant & Hamill LLC purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,439 shares of the company’s stock, valued at approximately $609,000.

Other hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. raised its holdings in shares of Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after purchasing an additional 833 shares during the last quarter. Global Retirement Partners LLC acquired a new position in Arcutis Biotherapeutics during the fourth quarter worth $35,000. EverSource Wealth Advisors LLC grew its position in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after purchasing an additional 698 shares in the last quarter. NewEdge Advisors LLC increased its stake in Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after buying an additional 1,045 shares during the last quarter. Finally, Truvestments Capital LLC increased its stake in Arcutis Biotherapeutics by 114.2% in the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after buying an additional 1,606 shares during the last quarter.

Insider Transactions at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 4,096 shares of Arcutis Biotherapeutics stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.41, for a total transaction of $99,983.36. Following the completion of the sale, the director owned 38,378 shares of the company’s stock, valued at approximately $936,806.98. This trade represents a 9.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue-Jean Lin sold 4,946 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.38, for a total transaction of $120,583.48. Following the completion of the sale, the director directly owned 27,567 shares of the company’s stock, valued at approximately $672,083.46. The trade was a 15.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 16,894 shares of company stock valued at $422,044. 9.40% of the stock is currently owned by company insiders.

Arcutis Biotherapeutics Stock Up 4.1%

Arcutis Biotherapeutics stock opened at $27.10 on Thursday. The company’s 50-day moving average price is $25.87 and its two-hundred day moving average price is $24.68. The company has a quick ratio of 2.46, a current ratio of 2.68 and a debt-to-equity ratio of 0.54. The stock has a market cap of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49. Arcutis Biotherapeutics, Inc. has a twelve month low of $13.69 and a twelve month high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The company had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. As a group, analysts expect that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Analyst Ratings Changes

A number of research firms have recently commented on ARQT. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.